Table 3. Characteristics of the... | American Society of Hematology

Table 3.

Characteristics of the responders following decitabine therapy

				BM blast %
Patient no.	Age, y/sex	Diagnosis	Salvage no.	Before	After	Karyotype	Dose, mg/m² × days	Response	Response duration, wk	Survival, wk
6	65/M	AML	1	41	0	-5/-7	5 × 10	CR	7	18
11	31/M	AML	2	16	3	t(3;3)	10 × 10	CR	21	62
20	55/F	AML	1	11	0	Diploid	15 × 10	HI	4	29
41	77/M	AML	1	35	2	Diploid	15 × 10	HI	4	43
44	78/M	AML	2	8	2	Diploid	15 × 10	HI	2	44
16	65/M	AML	1	60	3	-7	15 × 10	CR	17	35
19	48/F	AML	3	72	4	Diploid	15 × 10	CR	7	47
50	27/F	AML	4	5	0	Diploid	15 × 10	CR	59+	60+
48	21/F	MDS	0	13	1	Diploid	15 × 10	HI	13	16
17	72/M	MDS	1	9	1	-5/-7	15 × 10	CR	29	50
33	83/M	MDS	0	20	2	5q-, +8	15 × 15	CR	48	61+
22	64/M	MDS	1	10	1	+8 (100)	20 × 10	HI	1	44
7	43/M	CML	1	18	2	Ph (100)	5 × 10	PHR	8	111+
18	69/M	CML	1	1	0	Ph	15 × 10	CHR	9	19
43	45/F	CML	2	30	6	Ph+ other	15 × 10	2nd CP	1	20
46	55/M	CML	3	27	3	Ph+ other	15 × 10	CHR	8	28

				BM blast %
Patient no.	Age, y/sex	Diagnosis	Salvage no.	Before	After	Karyotype	Dose, mg/m² × days	Response	Response duration, wk	Survival, wk
6	65/M	AML	1	41	0	-5/-7	5 × 10	CR	7	18
11	31/M	AML	2	16	3	t(3;3)	10 × 10	CR	21	62
20	55/F	AML	1	11	0	Diploid	15 × 10	HI	4	29
41	77/M	AML	1	35	2	Diploid	15 × 10	HI	4	43
44	78/M	AML	2	8	2	Diploid	15 × 10	HI	2	44
16	65/M	AML	1	60	3	-7	15 × 10	CR	17	35
19	48/F	AML	3	72	4	Diploid	15 × 10	CR	7	47
50	27/F	AML	4	5	0	Diploid	15 × 10	CR	59+	60+
48	21/F	MDS	0	13	1	Diploid	15 × 10	HI	13	16
17	72/M	MDS	1	9	1	-5/-7	15 × 10	CR	29	50
33	83/M	MDS	0	20	2	5q-, +8	15 × 15	CR	48	61+
22	64/M	MDS	1	10	1	+8 (100)	20 × 10	HI	1	44
7	43/M	CML	1	18	2	Ph (100)	5 × 10	PHR	8	111+
18	69/M	CML	1	1	0	Ph	15 × 10	CHR	9	19
43	45/F	CML	2	30	6	Ph+ other	15 × 10	2nd CP	1	20
46	55/M	CML	3	27	3	Ph+ other	15 × 10	CHR	8	28